Clinuvel Pharmaceuticals Limited (AU:CUV)
ASX:CUV
Top Page
Clinuvel Pharmaceuticals
(Sydney:CUV)
Select Model
Select Model
Rating:72Outperform
Price Target:
AU$11.00
▼(-0.72% Downside)
Action:ReiteratedDate:02/28/26
The score is supported primarily by strong financial performance (profitability, cash strength, and minimal leverage) and a generally positive earnings update (growth, cash build, and clinical progress). This is tempered by weak technical signals (below key moving averages with negative MACD) and only moderate valuation support.
Positive Factors
Balance sheet strength
A long-established debt-free position and a 22% increase in cash reserves provide durable financial flexibility. This supports ongoing R&D, commercial roll-out and dividend policy, reduces refinancing risk and buffers operational volatility over the next several quarters.
Negative Factors
Product concentration risk
Dependence on a single marketed product concentrates commercial and regulatory risk: any adverse payer decisions, safety events or competitive entrants could materially affect revenues and cash generation. Diversification remains limited over the next several quarters.
Read all positive and negative factors
Positive Factors
Negative Factors
Balance sheet strength
A long-established debt-free position and a 22% increase in cash reserves provide durable financial flexibility. This supports ongoing R&D, commercial roll-out and dividend policy, reduces refinancing risk and buffers operational volatility over the next several quarters.
Read all positive factors
Clinuvel Pharmaceuticals (CUV) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$483.43M
Dividend Yield0.38%
Average Volume (3M)97.23K
Price to Earnings (P/E)15.0
Beta (1Y)0.62
Revenue Growth7.76%
EPS Growth1.55%
CountryAU
Employees16
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)0.21
Shares Outstanding50,200,740
10 Day Avg. Volume118,433
30 Day Avg. Volume97,231
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)2.16
Price to Sales (P/S)5.47
P/FCF Ratio12.74
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$20.80Price Target Upside87.70% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)0.71
Revenue Forecast (FY)AU$99.25M
Clinuvel Pharmaceuticals Business Overview & Revenue Model
Company Description
Clinuvel Pharmaceuticals Limited is a biopharmaceutical company focused on developing and commercializing innovative therapies for patients with severe skin disorders and other related conditions. The company operates primarily in the healthcare s...
How the Company Makes Money
Clinuvel Pharmaceuticals generates revenue primarily through the sale of its flagship product, SCENESSE, which is marketed in several countries for the treatment of EPP. The company has established a pricing strategy based on the unique value prop...
Clinuvel Pharmaceuticals Earnings Call Summary
Earnings Call Date:Aug 27, 2025
(Q4-2025)
| % Change Since: |
Next Earnings Date:Sep 01, 2026
Earnings Call Sentiment Positive
The earnings call highlighted strong revenue growth, a solid financial position, and significant progress in clinical trials, despite increased expenses and a regulatory setback. The company's expansion in the U.S. and consistent profitability were notable achievements. However, delays in revenue recognition and increased operational costs posed challenges.Positive Updates
Record Revenue Growth
Revenues increased by 10% to $105 million, breaking the $100 million barrier for the first time. This included a 6% growth in commercial sales and a 24% growth in sales reimbursements, primarily driven by expansion in the U.S. and Europe.
Negative Updates
Increased Expenses
Expenses increased by 20%, with personnel costs rising 31% due to additional skills and new employees. Commercial distribution costs were up 10%.
Read all updates
Q4-2025 Updates
Positive
Negative
Record Revenue Growth
Revenues increased by 10% to $105 million, breaking the $100 million barrier for the first time. This included a 6% growth in commercial sales and a 24% growth in sales reimbursements, primarily driven by expansion in the U.S. and Europe.
Read all positive updates
Company Guidance
During CLINUVEL's investor webinar, several key financial metrics and operational highlights for the fiscal year ending June 30, 2025, were discussed. The company reported a 10% increase in revenue, reaching $105 million, driven by a 6% growth in commercial sales in the U.S. and Europe. Sales reimbursements grew by 24%, and U.S. expansion was bolstered by 104 trained and accredited sites, aiming for 120 by year-end. Interest income from term deposits rose by 29%, despite a 20% increase in expenses, which focused on reinvestment in R&D and employee development. Notable achievements included a ninth consecutive annual profit, an eighth consecutive annual dividend, and a 22% increase in cash reserves. The company's net tangible asset backing rose by 19%, with a net profit margin of 34% and a 35% revenue CAGR over nine years. Additionally, CLINUVEL remained debt-free for the 20th consecutive year, with significant cash reserves providing a strong operational buffer. The company also highlighted its ongoing clinical trials and expansion efforts, including the fully recruited Phase III CUV105 vitiligo trial.Clinuvel Pharmaceuticals Financial Statement Overview
Summary
Income Statement
85
Very Positive
Balance Sheet
90
Very Positive
Cash Flow
80
Positive
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 96.30M | 95.02M | 88.18M | 78.32M | 65.72M | 47.98M |
| Gross Profit | 61.36M | 79.14M | 80.45M | 50.59M | 46.62M | 35.20M |
| EBITDA | 41.65M | 57.20M | 56.28M | 46.37M | 35.08M | 28.19M |
| Net Income | 32.54M | 36.17M | 35.64M | 30.60M | 20.88M | 24.73M |
Balance Sheet | ||||||
| Total Assets | 269.70M | 271.75M | 231.12M | 194.52M | 144.81M | 108.57M |
| Cash, Cash Equivalents and Short-Term Investments | 233.00M | 224.11M | 183.87M | 156.81M | 121.51M | 82.69M |
| Total Debt | 341.09K | 528.53K | 879.78K | 999.87K | 1.26M | 1.30M |
| Total Liabilities | 20.68M | 30.94M | 28.11M | 29.89M | 19.25M | 9.83M |
| Stockholders Equity | 249.02M | 240.81M | 203.01M | 164.63M | 125.56M | 98.74M |
Cash Flow | ||||||
| Free Cash Flow | 40.08M | 40.80M | 31.48M | 35.88M | 39.44M | 18.41M |
| Operating Cash Flow | 40.47M | 41.10M | 37.05M | 36.91M | 39.87M | 19.26M |
| Investing Cash Flow | -18.64M | -47.72M | -29.03M | -1.03M | -434.44K | -854.33K |
| Financing Cash Flow | -2.71M | -2.94M | -3.57M | -2.24M | -1.50M | -1.48M |
Clinuvel Pharmaceuticals Technical Analysis
Negative
11.08
Price Trends
11.06
Negative
11.47
Negative
11.42
Negative
Market Momentum
-0.42
Negative
39.20
Neutral
30.93
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:CUV, the sentiment is Negative. The current price of 11.08 is above the 20-day moving average (MA) of 10.09, above the 50-day MA of 11.06, and below the 200-day MA of 11.42, indicating a bearish trend. The MACD of -0.42 indicates Negative momentum. The RSI at 39.20 is Neutral, neither overbought nor oversold. The STOCH value of 30.93 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:CUV.
Clinuvel Pharmaceuticals Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
72 Outperform | AU$483.43M | 14.96 | 13.29% | 0.38% | 7.76% | 1.55% | |
53 Neutral | AU$90.94M | -2.00 | -131.13% | ― | 456.50% | -457.14% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | AU$1.16B | -10.86 | -30.03% | ― | ― | -5.70% | |
47 Neutral | AU$1.14B | -5.54 | -54.37% | ― | ― | -29.93% | |
42 Neutral | AU$738.77M | -4.51 | 132.37% | ― | -80.08% | 59.91% | |
40 Underperform | AU$70.74M | -3.40 | -35.86% | ― | ― | -19.21% |
* Healthcare Sector Average
AU:CUV
Clinuvel Pharmaceuticals
9.63
-2.01
-17.29%
AU:OPT
Opthea
0.60
0.00
0.00%
AU:IMM
Immutep Ltd
0.05
-0.24
-84.14%
AU:PYC
PYC Therapeutics Limited
1.18
-0.14
-10.47%
AU:CU6
Clarity Pharmaceuticals Ltd.
3.07
0.63
25.82%
AU:BOT
Botanix Pharmaceuticals Limited
0.04
-0.44
-91.58%
Clinuvel Pharmaceuticals Corporate Events
Clinuvel Profit Dips on Higher Expansion Costs Despite Record Half-Year Revenue
Feb 26, 2026
Clinuvel Pharmaceuticals reported a 4% rise in half-year revenues to A$36.9 million, driven by increased commercial and Special Access Scheme sales of its flagship drug SCENESSE for erythropoietic protoporphyria and higher interest income on large...
Clinuvel Flags Wide-Ranging Risks Ahead of Institutional Investor Meetings
Feb 1, 2026
Clinuvel Pharmaceuticals has issued an update noting its ongoing clinical and financial activities ahead of institutional investor meetings hosted by Jefferies, while emphasizing the inherent uncertainty in its forward-looking statements. The comp...
Clinuvel Starts Preclinical Dosing of New Controlled-Release Peptide Platform VLRX-L
Jan 11, 2026
Clinuvel Pharmaceuticals has begun dosing in a new preclinical study of VLRX-L, its in-house developed controlled-release liquid injectable peptide platform designed to deliver melanocortin-based and other peptide drugs with reproducible release p...
Clinuvel Reports New Positive Vitiligo Data for SCENESSE® in Darker-Skinned Patients
Jan 7, 2026
Clinuvel Pharmaceuticals has reported new clinical data from four Fitzpatrick VI (darker skin type) adult patients enrolled in its ongoing CUV105 study evaluating SCENESSE® in vitiligo, presented at the Regional Dermatology Training Center co...
Clinuvel Pharmaceuticals Reports Lapse of 5,425 Performance Rights
Jan 1, 2026
Clinuvel Pharmaceuticals Limited, an Australian listed biopharmaceutical company trading on the ASX under the code CUV, focuses on developing and commercialising pharmaceutical products. The company has announced the lapse of 5,425 performance rig...
Clinuvel Files U.S. GAAP 20-F as It Targets Nasdaq ADR Uplisting
Dec 18, 2025
Clinuvel Pharmaceuticals has filed a draft registration statement, including a U.S. GAAP-compliant Form 20-F annual report for the year to 30 June 2025, with the U.S. Securities and Exchange Commission as it moves to upgrade its American Depositar...
CLINUVEL Expands Singapore RD&I Centre for Advanced Peptide Therapies
Dec 7, 2025
CLINUVEL PHARMACEUTICALS LTD has announced a significant expansion of its VALLAURIX Research, Development, and Innovation Centre in Singapore, supported by the Singapore Economic Development Board. This strategic five-year investment aims to trans...
CLINUVEL Targets Mid-2026 for European Filing of NEURACTHEL® Instant
Dec 2, 2025
CLINUVEL Pharmaceuticals announced a significant milestone with the planned mid-2026 European regulatory filing for NEURACTHEL® Instant, a generic adrenocorticotropic hormone (ACTH) formulation. This follows the successful validation of the m...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.